in vitro News and Research

RSS

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.

14 Jan 2015

Crown Bioscience to double capacity of PRECOS facility, rename UK site

Crown Bioscience, Inc., a leading global drug discovery and development service company, has announced that it will double the capacity of the recently acquired PRECOS (Preclinical Oncology Services Limited) facility and will rename the site Crown Bioscience UK Ltd.

9 Jan 2015

FDA provides Emergency Use Authorization for Roche's LightMix Ebola Zaire rRT-PCR Test

Roche today announced that the U.S. Food and Drug Administration has provided an Emergency Use Authorization (EUA) for the LightMix Ebola Zaire rRT-PCR Test for use on patients with signs and symptoms of Ebola Zaire virus infection in conjunction with epidemiological risk factors, such as individuals traveling from West Africa.

From Roche Sequencing and Life Science 30 Dec 2014

Scientists image zinc atoms released by fertilized mammalian egg

Sparks literally fly when a sperm and an egg hit it off. The fertilized mammalian egg releases from its surface billions of zinc atoms in "zinc sparks," one wave after another, found a Northwestern University-led interdisciplinary research team that includes experts from the U.S. Department of Energy's Advanced Photon Source at Argonne National Laboratory.

24 Dec 2014

Researchers devise new technique to understand how neutrophils move in bodily tissues

Neutrophils, a type of white blood cell, are the immune system's all-terrain vehicles. The cells are recruited to fight infections or injury in any tissue or organ in the body despite differences in the cellular and biochemical composition.

22 Dec 2014

Canopus BioPharma study confirms efficacy of CB008 drug for Ebola Virus inhibition

Canopus BioPharma Inc. today announces that it has completed crucial research in confirming efficacy of a prescription drug: CB008 for Ebola Virus inhibition.

19 Dec 2014

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157.

18 Dec 2014

New study identifies how SNAIL gene helps cancer cells break free from primary tumor

More than 90 percent of cancer-related deaths are caused by the spread of cancer cells from their primary tumor site to other areas of the body. A new study has identified how one important gene helps cancer cells break free from the primary tumor.

18 Dec 2014

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in the development of monoclonal antibodies for cancer, today announce the extension of their partnership to develop the 3C23K antibody for the treatment of gynecological cancers.

16 Dec 2014

Photoacoustic imaging has potential to be used as noninvasive method to detect cervical cancer

Cervical cancer is, in many ways, a shining example of how successful the war on cancer can be. Thanks largely to the advent of Pap smear screening, U.S. cervical cancer deaths decreased dramatically, by more than 60 percent, between 1955 and 1992. In the last two decades, better treatment outcomes and more powerful imaging techniques have steadily pushed 5-year survival rates ever higher.

15 Dec 2014

ETH Zurich, University of Zurich jointly open new translational research centre

ETH Zurich and the University of Zurich are taking their long-standing partnership to a new level with a new translational research centre. The two universities are founding the Wyss Translational Center Zurich (WTZ) with funds donated by Hansjörg Wyss to the ETH Zurich Foundation.

14 Dec 2014

Andor's Komet software used to automatically score modified 3D 'Comet' assay results

With cancer rates rising worldwide, and Cancer Research UK predicting that the lifetime risk of cancer will reach 50% by 2027, the need for early diagnosis is overwhelming. Now, a British research group has published details of a simple empirical test to detect any early-stage cancer, relying on Andor's Komet software to automatically score the modified 3D 'Comet' assay results.

From Andor Technology Ltd. 11 Dec 2014

Scientists report new family of selective molecules to combat causal agent of malaria

Malaria is one of the most serious health problems worldwide, registering 200 million clinical cases and more than 600,000 attributable deaths per year, according to information from the World Health Organization in 2013. Given the emerging resistance to the standard treatment most widely used throughout the world, which is based on artemisinin and its analogs, there is a need for new antimalarial compounds.

11 Dec 2014

New study investigates Ebola protein

A new study by Robert Stahelin, an adjunct associate professor of chemistry and biochemistry at the University of Notre Dame and an associate professor at the Indiana University School of Medicine-South Bend, as well as a member of Notre Dame's Eck Institute for Global Health, investigates how the most abundant protein that composes the Ebola virus, VP 40, mediates replication of a new viral particle.

11 Dec 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy.

10 Dec 2014

University of Illinois study could provide insight into protein-misfolding diseases

When a large protein unfolds in transit through a cell, it slows down and can get stuck in traffic. Using a specialized microscope -- a sort of cellular traffic camera -- University of Illinois chemists now can watch the way the unfolded protein diffuses.

10 Dec 2014

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).

10 Dec 2014

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

As the 2014-2015 flu season begins, Focus Diagnostics, the products business of Quest Diagnostics, today announced that its Simplexa Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter.

From Quest Diagnostics 9 Dec 2014

MD Anderson study sheds light on miR569 gene

A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.

9 Dec 2014

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).

8 Dec 2014

in vitro News and Research

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

Crown Bioscience to double capacity of PRECOS facility, rename UK site

FDA provides Emergency Use Authorization for Roche's LightMix Ebola Zaire rRT-PCR Test

Scientists image zinc atoms released by fertilized mammalian egg

Researchers devise new technique to understand how neutrophils move in bodily tissues

Canopus BioPharma study confirms efficacy of CB008 drug for Ebola Virus inhibition

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

New study identifies how SNAIL gene helps cancer cells break free from primary tumor

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

Photoacoustic imaging has potential to be used as noninvasive method to detect cervical cancer

ETH Zurich, University of Zurich jointly open new translational research centre

Andor's Komet software used to automatically score modified 3D 'Comet' assay results

Scientists report new family of selective molecules to combat causal agent of malaria

New study investigates Ebola protein

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

University of Illinois study could provide insight into protein-misfolding diseases

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

MD Anderson study sheds light on miR569 gene

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News